Information  X 
Enter a valid email address

EPIC/TIDM matching '0H7R'

Date
Time Source
Company
Announcement
10 Aug 2020 9:01 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
06 May 2020 9:14 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
27 Mar 2020 10:19 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
17 Mar 2020 11:30 am GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
16 Mar 2020 8:20 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
12 Feb 2020 7:15 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
21 Jan 2020 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
13 Jan 2020 2:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
24 Dec 2019 6:01 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20 Dec 2019 3:44 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
  2:24 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
19 Dec 2019 10:20 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
09 Dec 2019 1:45 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
12 Nov 2019 9:30 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
21 Oct 2019 2:15 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
03 Sep 2019 2:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Strategic Review
09 Aug 2019 9:15 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
25 Jul 2019 2:15 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA
26 Jun 2019 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
18 Jun 2019 1:29 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
21 May 2019 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
14 May 2019 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
10 May 2019 9:15 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
08 May 2019 1:30 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
01 May 2019 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting
30 Apr 2019 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
15 Apr 2019 7:41 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
04 Apr 2019 1:25 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
18 Mar 2019 8:45 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
31 Jan 2019 1:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
09 Nov 2018 9:20 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
05 Nov 2018 12:00 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
18 Oct 2018 1:03 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
12 Sep 2018 1:45 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
09 Aug 2018 9:20 pm GNW Factsheet Abeona Therapeutics Inc. (0H7R) Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
11 May 2018 1:15 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
23 Apr 2018 1:15 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
20 Apr 2018 1:15 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
02 Apr 2018 1:15 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
16 Mar 2018 9:32 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
07 Feb 2018 1:45 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
02 Feb 2018 1:45 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
29 Jan 2018 1:45 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
20 Dec 2017 1:45 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
15 Nov 2017 1:25 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
13 Nov 2017 1:45 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Management to Present at Multiple Conferences in November
09 Nov 2017 1:45 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
04 Oct 2017 1:52 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
16 Aug 2017 2:38 pm GNW Factsheet Abeona Therapeutics Inc (0H7R) Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A


Company Announcements Archive »


a d v e r t i s e m e n t